vs

Side-by-side financial comparison of Fastly, Inc. (FSLY) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $172.6M, roughly 1.2× Fastly, Inc.). Fastly, Inc. runs the higher net margin — -9.0% vs -62.0%, a 53.0% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 22.8%). Fastly, Inc. produced more free cash flow last quarter ($12.2M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 13.7%).

Fastly, Inc. is an American company based in San Francisco, which describes itself as a cloud computing company. Fastly provides content delivery network services, image optimization, and load balancing services. Fastly's cloud security services include denial-of-service attack protection, bot mitigation, and a web application firewall.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

FSLY vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.2× larger
RARE
$207.3M
$172.6M
FSLY
Growing faster (revenue YoY)
RARE
RARE
+3.1% gap
RARE
25.9%
22.8%
FSLY
Higher net margin
FSLY
FSLY
53.0% more per $
FSLY
-9.0%
-62.0%
RARE
More free cash flow
FSLY
FSLY
$113.0M more FCF
FSLY
$12.2M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
13.7%
FSLY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FSLY
FSLY
RARE
RARE
Revenue
$172.6M
$207.3M
Net Profit
$-15.5M
$-128.6M
Gross Margin
61.4%
Operating Margin
-8.7%
-54.7%
Net Margin
-9.0%
-62.0%
Revenue YoY
22.8%
25.9%
Net Profit YoY
52.9%
3.5%
EPS (diluted)
$-0.10
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FSLY
FSLY
RARE
RARE
Q4 25
$172.6M
$207.3M
Q3 25
$158.2M
$159.9M
Q2 25
$148.7M
$166.5M
Q1 25
$144.5M
$139.3M
Q4 24
$140.6M
$164.6M
Q3 24
$137.2M
$139.5M
Q2 24
$132.4M
$147.0M
Q1 24
$133.5M
$108.8M
Net Profit
FSLY
FSLY
RARE
RARE
Q4 25
$-15.5M
$-128.6M
Q3 25
$-29.5M
$-180.4M
Q2 25
$-37.5M
$-115.0M
Q1 25
$-39.1M
$-151.1M
Q4 24
$-32.9M
$-133.2M
Q3 24
$-38.0M
$-133.5M
Q2 24
$-43.7M
$-131.6M
Q1 24
$-43.4M
$-170.7M
Gross Margin
FSLY
FSLY
RARE
RARE
Q4 25
61.4%
Q3 25
58.4%
Q2 25
54.5%
Q1 25
53.2%
Q4 24
53.4%
Q3 24
54.5%
Q2 24
55.1%
Q1 24
54.8%
Operating Margin
FSLY
FSLY
RARE
RARE
Q4 25
-8.7%
-54.7%
Q3 25
-18.2%
-106.9%
Q2 25
-24.8%
-64.8%
Q1 25
-26.4%
-102.6%
Q4 24
-24.4%
-74.3%
Q3 24
-29.6%
-94.6%
Q2 24
-35.3%
-79.1%
Q1 24
-34.6%
-151.9%
Net Margin
FSLY
FSLY
RARE
RARE
Q4 25
-9.0%
-62.0%
Q3 25
-18.6%
-112.8%
Q2 25
-25.2%
-69.0%
Q1 25
-27.1%
-108.5%
Q4 24
-23.4%
-80.9%
Q3 24
-27.7%
-95.7%
Q2 24
-33.0%
-89.5%
Q1 24
-32.5%
-156.8%
EPS (diluted)
FSLY
FSLY
RARE
RARE
Q4 25
$-0.10
$-1.28
Q3 25
$-0.20
$-1.81
Q2 25
$-0.26
$-1.17
Q1 25
$-0.27
$-1.57
Q4 24
$-0.23
$-1.34
Q3 24
$-0.27
$-1.40
Q2 24
$-0.32
$-1.52
Q1 24
$-0.32
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FSLY
FSLY
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$361.8M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$929.6M
$-80.0M
Total Assets
$1.5B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FSLY
FSLY
RARE
RARE
Q4 25
$361.8M
$421.0M
Q3 25
$342.9M
$202.5M
Q2 25
$321.2M
$176.3M
Q1 25
$307.3M
$127.1M
Q4 24
$295.9M
$174.0M
Q3 24
$308.2M
$150.6M
Q2 24
$311.8M
$480.7M
Q1 24
$329.5M
$112.3M
Stockholders' Equity
FSLY
FSLY
RARE
RARE
Q4 25
$929.6M
$-80.0M
Q3 25
$937.0M
$9.2M
Q2 25
$942.6M
$151.3M
Q1 25
$957.0M
$144.2M
Q4 24
$965.3M
$255.0M
Q3 24
$969.5M
$346.8M
Q2 24
$981.2M
$432.4M
Q1 24
$991.8M
$140.3M
Total Assets
FSLY
FSLY
RARE
RARE
Q4 25
$1.5B
$1.5B
Q3 25
$1.5B
$1.2B
Q2 25
$1.5B
$1.3B
Q1 25
$1.4B
$1.3B
Q4 24
$1.5B
$1.5B
Q3 24
$1.5B
$1.5B
Q2 24
$1.5B
$1.6B
Q1 24
$1.5B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FSLY
FSLY
RARE
RARE
Operating Cash FlowLast quarter
$22.4M
$-99.8M
Free Cash FlowOCF − Capex
$12.2M
$-100.8M
FCF MarginFCF / Revenue
7.1%
-48.6%
Capex IntensityCapex / Revenue
5.9%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$65.8M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FSLY
FSLY
RARE
RARE
Q4 25
$22.4M
$-99.8M
Q3 25
$28.9M
$-91.4M
Q2 25
$25.8M
$-108.3M
Q1 25
$17.3M
$-166.5M
Q4 24
$5.2M
$-79.3M
Q3 24
$5.0M
$-67.0M
Q2 24
$-4.9M
$-77.0M
Q1 24
$11.1M
$-190.7M
Free Cash Flow
FSLY
FSLY
RARE
RARE
Q4 25
$12.2M
$-100.8M
Q3 25
$22.9M
$-92.7M
Q2 25
$15.9M
$-110.7M
Q1 25
$14.7M
$-167.8M
Q4 24
$251.0K
$-79.5M
Q3 24
$3.0M
$-68.6M
Q2 24
$-6.7M
$-79.0M
Q1 24
$9.5M
$-193.9M
FCF Margin
FSLY
FSLY
RARE
RARE
Q4 25
7.1%
-48.6%
Q3 25
14.5%
-58.0%
Q2 25
10.7%
-66.5%
Q1 25
10.2%
-120.5%
Q4 24
0.2%
-48.3%
Q3 24
2.2%
-49.2%
Q2 24
-5.1%
-53.7%
Q1 24
7.1%
-178.2%
Capex Intensity
FSLY
FSLY
RARE
RARE
Q4 25
5.9%
0.5%
Q3 25
3.8%
0.8%
Q2 25
6.6%
1.5%
Q1 25
1.8%
1.0%
Q4 24
3.5%
0.1%
Q3 24
1.5%
1.2%
Q2 24
1.3%
1.4%
Q1 24
1.2%
3.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FSLY
FSLY

Network Services$130.8M76%
Security$35.4M21%
Other$6.4M4%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons